Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07491081Not ApplicableRecruiting

EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection

Role: collaborator

NCT06522854Phase 3Withdrawn

Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings

Role: collaborator

NCT06461429Not ApplicableNot Yet Recruiting

PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]

Role: collaborator

NCT01385644Phase 1Completed

A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis

Role: collaborator

All 4 trials loaded